Bridge to Life™ Attains FDA Approval for VitaSmart™ HOPE System
Bridge to Life™ Ltd. has made significant strides in organ preservation technology by securing FDA De Novo clearance for its innovative VitaSmart™ Hypothermic Oxygenated Perfusion (HOPE) System. This revolutionary device is the first of its kind to receive approval in the U.S. for hypothermic oxygenated perfusion in donor livers.
A New Era for Liver Transplantation
The recent FDA approval opens the door for using the VitaSmart™ system in clinical settings. It showcases a regulated process for U.S. transplant centers to adopt HOPE protocols. The clearance was announced, highlighting the importance of this development for liver transplants.
Impact on Donation after Circulatory Death (DCD)
One exciting aspect of this advancement is the capacity to utilize organs from DCD donors, expanding the donor pool significantly. The inclusion of DCD liver grafts in the approved labeling aligns with a growing trend focused on improving preservation strategies for better transplant outcomes.
Significant Milestones in Transplant Technology
"This FDA clearance signifies a remarkable advancement for Bridge to Life, enhancing liver transplantation efforts in the nation," remarked Don Webber, the CEO and President of Bridge to Life™ Ltd.
With the VitaSmart™ system, clinicians can perform hypothermic oxygenated perfusion before transplantation within established protocols, effectively improving organ utilization.
Supportive Labeling for Clinicians
One of the key benefits of the FDA-approved labeling is its flexibility, allowing for the use of hypothermic perfusion without any set maximum duration. This empowers medical professionals to apply their clinical judgment effectively.
Comprehensive Features of the VitaSmart™ System
VitaSmart™ offers an array of valuable features that integrate seamlessly into existing transplant workflows, emphasizing:
- Enhanced integration of hypothermic oxygenated perfusion
- Flexible preservation strategies for liver grafts
- Center-friendly approach without the complexities of transportation
These benefits make the VitaSmart™ system both economically viable and easy to adopt.
Robust Clinical Evidence
The FDA's decision was bolstered by findings from the Bridge to HOPE clinical trial, which evaluated the efficacy of the HOPE technology across various transplant centers. Involving 219 recipients, the trial focused on the device’s performance with both DBD and DCD donors.
Efficacy and Safety
The results yielded a strong safety profile alongside notable improvements in early graft function, further validating the use of the VitaSmart™ system in clinical practices.
Operational and Economic Advantages
VitaSmart™ is tailored to enhance operational efficiency in transplant centers, offering:
- Improved organ usage rates
- Reduction in resource utilization
- Simplified workflows without transport complications
Such advantages position the VitaSmart™ system as a favorable option for medical institutions navigating the challenges of transplantation.
Designed for Real-World Application
The technology behind VitaSmart™ facilitates controlled hypothermic temperatures, ensuring optimal perfusion and preparation of donor livers prior to their transplantation. Its design prioritizes reliability and user-friendliness, making it suitable for various transplant environments.
Gratitude to Contributors
Webber expressed deep appreciation for the dedication of investigators and transplant teams involved in advancing the Bridge to HOPE study. Their collaborative efforts and commitment to clinical excellence paved the way for this significant achievement in organ preservation.
About Bridge to Life™ Ltd.
As a leader in organ preservation, Bridge to Life™ Ltd. specializes in advanced preservation solutions, including products like Belzer UW®, EasiSlush®, and the VitaSmart™ system. Their mission is to work closely with transplant centers globally, driving innovation in preservation science to support crucial transplantation efforts.
Frequently Asked Questions
What is the VitaSmart™ HOPE System?
The VitaSmart™ HOPE system is an FDA-cleared device designed for hypothermic oxygenated perfusion of donor livers before transplantation.
How does this clearance affect DCD donor utilization?
This clearance significantly expands the potential for utilizing livers from Donation after Circulatory Death donors, enhancing the available donor pool.
What are the benefits of using VitaSmart™?
The system improves organ utilization, simplifies workflows, and allows for flexible preservation strategies.
What evidence supports the effectiveness of the VitaSmart™ system?
The FDA’s approval was supported by results from a multicenter trial showcasing improved outcomes and strong safety profiles for liver grafts.
Why is this clearance significant for Bridge to Life™?
The clearance represents a transformative achievement for Bridge to Life™, positioning them as innovators in the organ preservation landscape.
